Br
Non vérifié

Bristol Myers Squibb

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté
08/12/2025
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
1.00
03/12/2025
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
1.00
01/12/2025
Événements
Expos
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
1.00
26/11/2025
Événements
Biotechnologie
Industrie pharmaceutique
Santé
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
1.00
24/11/2025
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
1.00
24/11/2025
Web et Réseaux Sociaux
Événements
Biotechnologie
Industrie pharmaceutique
Santé
Bristol Myers Squibb to Host Hematology-Focused Investor Event
1.00
18/11/2025
Finance
Biotechnologie
Industrie pharmaceutique
Santé
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
1.00
18/11/2025
Biotechnologie
Finance
Santé
Associations/Professionnels
Industrie pharmaceutique
Titres et actions
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
1.00
14/11/2025
Marché du travail
Industrie
Biotechnologie
Industrie pharmaceutique
Santé
Médecine - Divers
Update on Phase 3 Librexia ACS Trial
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0